Evidence map›Paper›PMID 37970074›Full record

ArticleAccess microbiology2023

John Merlino, Sophia Rizzo, Suzanne English, Sai Rupa Baskar, Steven Siarakas, Genevieve Mckew, Shelanah Fernanado, Timothy Gray

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Access microbiology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.2field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Genomic profiling of cefotaxime-resistantFrontiers in microbiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

John MerlinoDepartment of Microbiology and Infectious Diseases, Concord Hospital, NSW Health Pathology, NSW Health, Concord, Australia.ORCID https://orcid.org/0000-0002-0855-8995
Sophia RizzoDepartment of Microbiology and Infectious Diseases, Concord Hospital, NSW Health Pathology, NSW Health, Concord, Australia.
Suzanne EnglishDepartment of Microbiology and Infectious Diseases, Concord Hospital, NSW Health Pathology, NSW Health, Concord, Australia.
Sai Rupa BaskarDepartment of Microbiology and Infectious Diseases, Concord Hospital, NSW Health Pathology, NSW Health, Concord, Australia.
Steven SiarakasDepartment of Microbiology and Infectious Diseases, Concord Hospital, NSW Health Pathology, NSW Health, Concord, Australia.
Genevieve MckewDepartment of Microbiology and Infectious Diseases, Concord Hospital, NSW Health Pathology, NSW Health, Concord, Australia.
Shelanah FernanadoDepartment of Microbiology and Infectious Diseases, Concord Hospital, NSW Health Pathology, NSW Health, Concord, Australia.
Timothy GrayDepartment of Microbiology and Infectious Diseases, Concord Hospital, NSW Health Pathology, NSW Health, Concord, Australia.
Concord Repatriation General Hospital · AUThe University of Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: In this comparative case study, we discuss clinically relevant discrepancies of antimicrobial susceptibility testing (AST) interpretation for ceftriaxone against a non-typable, beta-lactamase negative, ampicillin-resistant (BLNAR) Case report: A 74-year-old man presented with a 3 day illness characterized by shortness of breath and dry cough, and was noted to be febrile and hypoxic on admission. A blood culture bottle flagged positive with Gram-negative coccobacilli, later identified as Conclusion: This discrepancy could lead to inconsistent reporting of susceptibilities between laboratories, and consequently antibiotic prescribing, especially for invasive isolates. As more laboratories adopt EUCAST methodologies for AST interpretation in Australia and globally, it is important for clinicians to consider the clinical implications of these methodological discrepancies.

Indexed as

BLNARcefotaximeceftriaxoneCLSIEUCASTHaemophilus influenzaeresistancesusceptibility

Identifiers

PMID37970074
PMCPMC10634490
OpenAlexW4387461113

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.